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Heroin Prescription and History
Virginia Berridge, Ph.D.
In this issue of the Journal, Oviedo-Joekes et al.1 
report on the results of the North American Opi-
ate Medication Initiative (NAOMI) trial compar-
ing methadone with injectable diacetylmorphine 
(the active ingredient in heroin) for the treat-
ment of heroin addiction. These data from North 
America point to a conclusion that has been wide-
ly supported, although not without controversy, by 
similar recent studies in Europe.2 The results of 
this trial may be added to those from Germany, 
the Netherlands, Spain, and Switzerland. Switzer-
land has 10 years of experience in the prescrip-
tion of heroin, and in a November 2008 referen-
dum, 68% of voters were in favor of its continued 
prescription. 
The prescription of heroin is rigidly controlled, 
and some commentators have asked whether a 
less restrictive and more clinical approach might 
make a difference to the proportion of drug us-
ers who are treated with heroin.3 Guidance on the 
prescription of heroin published by Britain’s Na-
tional Treatment Agency for Substance Misuse in 
2003 stressed that the drug should be prescribed 
as a last resort and under the medical control of 
a specialist.4 The prescription of heroin is now 
recognized in some European countries as the 
optimal treatment for patients for whom options 
are running out and in whom methadone main-
tenance has not worked, and it keeps the user in 
contact with drug services.
What Ashton and Witton have called a “role re-
versal” from killer drug to medical treatment is 
historically paradoxical.5 The emerging consensus 
is that heroin is a treatment for a limited number 
of illicit-drug users who do not do well with other 
medicines. Historically, however, heroin was the 
main “drug of choice” for treatment. In the 1920s 
and earlier in Britain, it was the treatment or 
maintenance drug for compliant middle-class ad-
dicts, those who accepted the authority of the doc-
tor to prescribe to them. The prescription of her-
oin was the basis of the so-called British system, 
which operated until the 1960s.6 This was not 
the case in the United States. The inability to con-
duct the NAOMI trial in the United States reflects 
a historically different attitude toward the medi-
cal prescription of heroin to addicts; this prohi-
bition dates back to the implementation of the 
1914 Harrison Narcotics Act before World War I. 
Doctors were prosecuted thereafter if they pre-
scribed heroin for addicts.7 The cross-national dif-
ference in heroin prescribing and the continued 
prescription of heroin in Britain owed much to 
the power of the British medical profession and to 
the low number of mainly middle-class addicts in 
the United Kingdom who took heroin. The per-
son with control of the drug and the sort of per-
son who was addicted were important.
Contextual issues like these, not the intrinsic 
properties of the drug itself, affected different na-
tional responses to treatment and to the prescrip-
tion of heroin; these issues also affected the change 
toward the use of methadone in the 1960s and 
1970s. The switch from abstinence from illicit-
drug use as the only legal option to the use of 
methadone took place under the influence of re-
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searchers Dole and Nyswander in New York.8 In 
the United States, methadone was associated with 
the ethos of a “medical” drug, whereas heroin was 
not.8 In the United Kingdom in the 1970s, the 
change came from prescribing heroin to prescrib-
ing methadone. That switch was also legitimated 
by a trial carried out by researchers Mitcheson and 
Hartnoll in the drug-dependence unit at London’s 
University College Hospital.9 They found that, as 
compared with the prescription of heroin, the pre-
scription of methadone was a more confronta-
tional method of treating addicts. It could force 
change even if it also brought greater involvement 
in the black market for heroin. It is recognized 
that the evidence from this trial, which is widely 
cited as the motivating force behind a switch from 
prescribing heroin to prescribing methadone on a 
short-term basis, was pushing at an already open 
door. It legitimated a change that was already un-
der way, which the psychiatrists who ran the clin-
ics wanted. The drug-dependence units had filled 
up with long-term heroin users. As Stimson and 
Oppenheimer noted in their classic study of the 
period, this switch provided a rationale for clin-
ic staff who longed for a therapeutic, rather than 
a shopkeeping, function.10 Professional interests 
again drove change.11
This episode of research and its effect on prac-
tice 30 years ago tell us something significant. 
The rise and fall of methods of treatment in this 
controversial area owe their rationale to evidence, 
but they also often owe more to the politics of 
the situation — to the context within which the 
evidence is received and to the interests that are 
prepared to support or oppose it. In Britain, the 
prescription of heroin is taking place on a small 
scale. However, it is more costly than methadone, 
which matters in a cost-conscious centralized 
health system, and few patients are receiving these 
prescriptions. Meanwhile, the “harm reduction” 
consensus about maintenance treatment overall 
is being questioned, primarily in relation to meth-
adone. As in the 1970s, clinic staff long for 
change, this time away from what one drug-
treatment worker called “methadone, wine, and 
welfare.” Researchers have pointed out that most 
illicit-drug users say they want to stop taking 
drugs. Conservative politicians have championed 
abstinence from illicit-drug use, and the media 
has asked why the treatment budget is so large if 
addicts just continue to take drugs. Hence, a re-
definition of the purpose of treatment and the 
nature of recovery is under discussion in the 
drug-treatment field. The consensus favoring 
maintenance with methadone as the major treat-
ment option may shift.
The treatment of addiction is a controversial 
matter, and practices that were once managed by 
specialists in-house and that were the subject of 
clinical discussion or publication in medical jour-
nals are now more open to a sometimes uncom-
prehending public gaze. Results such as those re-
ported in the NAOMI trial matter, but they do not 
operate in a vacuum. Countries have responded 
very differently to the findings reported so far. 
Switzerland and the Netherlands have integrated 
the prescription of heroin into their medical sys-
tems, while Germany and Spain have hesitated. 
In the mid-1990s, the Australian government dis-
continued a heroin trial. Will the “homegrown” 
results from the NAOMI trial have more impact 
in North America than the results from Europe? 
We will now wait to see what political or profes-
sional factors will support or oppose the con-
clusions of this study in its home territory, and 
whether the historical legacy of heroin will matter.
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